Subscribe
istock-895258514-natasaadzic
natasaadzic / iStockphoto.com
12 November 2018Big Pharma

UK life sciences bodies submit concerns over ‘no deal’ Brexit

Associations representing the pharmaceutical and biotechnology fields have said that the UK should maintain “close cooperation” with the EU post-Brexit, to ensure that access to safe and effective medicines continues in both markets.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Pharma owners warned of Brexit effect on TMs
22 November 2022   Large market for parallel or ‘grey’ imports of pharmaceuticals due to pricing differences in various countries | Govt consultation respondents unhappy with ‘lack of EU reciprocity’| Mewburn Ellis.
Big Pharma
Life sciences lawyers shocked and concerned amid Brexit uncertainty
17 January 2019   Lawyers have told LSIPR they are concerned about the continuing UK political uncertainty having a negative impact on life sciences investment and the Unified Patent Court.
Big Pharma
UK publishes further no-deal Brexit guidance for medicines
8 January 2019   The UK government has published further guidance on the regulation of medicines, medical devices and clinical trials in the event of a no-deal Brexit.


Editor's picks

Latham steps into dispute over $6bn treatment, replacing Kirkland
Americas
Latham steps into dispute over $6bn treatment, replacing Kirkland
13 August 2025

Editor's picks

Americas
Latham steps into dispute over $6bn treatment, replacing Kirkland
13 August 2025
Europe
In-house with Bayer: ‘Focus on quality early and stay close to inventors’
15 July 2025
Africa
Explainer: ARIPO’s role in Plant Variety Protection
15 July 2025
Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025
Europe
‘We created law’: G1/24 and the creation of the ‘diamond standard’
3 July 2025
Americas
Bankruptcy judge approves $305m sale of genetics testing company
1 July 2025

More on this story

Big Pharma
Pharma owners warned of Brexit effect on TMs
22 November 2022   Large market for parallel or ‘grey’ imports of pharmaceuticals due to pricing differences in various countries | Govt consultation respondents unhappy with ‘lack of EU reciprocity’| Mewburn Ellis.
Big Pharma
Life sciences lawyers shocked and concerned amid Brexit uncertainty
17 January 2019   Lawyers have told LSIPR they are concerned about the continuing UK political uncertainty having a negative impact on life sciences investment and the Unified Patent Court.
Big Pharma
UK publishes further no-deal Brexit guidance for medicines
8 January 2019   The UK government has published further guidance on the regulation of medicines, medical devices and clinical trials in the event of a no-deal Brexit.

More on this story

Big Pharma
Pharma owners warned of Brexit effect on TMs
22 November 2022   Large market for parallel or ‘grey’ imports of pharmaceuticals due to pricing differences in various countries | Govt consultation respondents unhappy with ‘lack of EU reciprocity’| Mewburn Ellis.
Big Pharma
Life sciences lawyers shocked and concerned amid Brexit uncertainty
17 January 2019   Lawyers have told LSIPR they are concerned about the continuing UK political uncertainty having a negative impact on life sciences investment and the Unified Patent Court.
Big Pharma
UK publishes further no-deal Brexit guidance for medicines
8 January 2019   The UK government has published further guidance on the regulation of medicines, medical devices and clinical trials in the event of a no-deal Brexit.

More features

Weil adds two more litigators from larger rival
Ninth Circuit revives trade secrets claims in DNA-sequencing spat
Latham steps into dispute over $6bn treatment, replacing Kirkland
Patent pollution: Emissions charter aims to clean up IP
Why Trump’s revenue-raising patent plan is riddled with problems
Harvard’s patent portfolio at risk as Trump turns up the pressure
Weil adds leaders from Latham to head up tech and life sciences
$740M deal ends COVID-19 vaccine feud between CureVac and BioNTech